FI3355913T3 - Muokatun j-ketjun sisältäviä sitoutuvia molekyylejä - Google Patents
Muokatun j-ketjun sisältäviä sitoutuvia molekyylejä Download PDFInfo
- Publication number
- FI3355913T3 FI3355913T3 FIEP16784320.0T FI16784320T FI3355913T3 FI 3355913 T3 FI3355913 T3 FI 3355913T3 FI 16784320 T FI16784320 T FI 16784320T FI 3355913 T3 FI3355913 T3 FI 3355913T3
- Authority
- FI
- Finland
- Prior art keywords
- igm
- chain
- adme
- binding molecule
- igg
- Prior art date
Links
- 101000840258 Homo sapiens Immunoglobulin J chain Proteins 0.000 claims 14
- 102100029571 Immunoglobulin J chain Human genes 0.000 claims 14
- 108010021625 Immunoglobulin Fragments Proteins 0.000 claims 9
- 102000008394 Immunoglobulin Fragments Human genes 0.000 claims 9
- 206010028980 Neoplasm Diseases 0.000 claims 4
- 201000011510 cancer Diseases 0.000 claims 4
- 102000009027 Albumins Human genes 0.000 claims 3
- 108010088751 Albumins Proteins 0.000 claims 3
- 102000004338 Transferrin Human genes 0.000 claims 3
- 108090000901 Transferrin Proteins 0.000 claims 3
- 108090000765 processed proteins & peptides Proteins 0.000 claims 3
- QMXCRMQIVATQMR-UHFFFAOYSA-N (2,5-dioxopyrrolidin-1-yl) 3-pyridin-2-ylsulfanylpropanoate Chemical group O=C1CCC(=O)N1OC(=O)CCSC1=CC=CC=N1 QMXCRMQIVATQMR-UHFFFAOYSA-N 0.000 claims 2
- 102100021257 Beta-secretase 1 Human genes 0.000 claims 2
- 101710150192 Beta-secretase 1 Proteins 0.000 claims 2
- 102000018866 Hyaluronan Receptors Human genes 0.000 claims 2
- 108010013214 Hyaluronan Receptors Proteins 0.000 claims 2
- 102100026120 IgG receptor FcRn large subunit p51 Human genes 0.000 claims 2
- 101710177940 IgG receptor FcRn large subunit p51 Proteins 0.000 claims 2
- 102000016267 Leptin Human genes 0.000 claims 2
- 108010092277 Leptin Proteins 0.000 claims 2
- 230000004927 fusion Effects 0.000 claims 2
- 230000002489 hematologic effect Effects 0.000 claims 2
- JJAHTWIKCUJRDK-UHFFFAOYSA-N succinimidyl 4-(N-maleimidomethyl)cyclohexane-1-carboxylate Chemical compound C1CC(CN2C(C=CC2=O)=O)CCC1C(=O)ON1C(=O)CCC1=O JJAHTWIKCUJRDK-UHFFFAOYSA-N 0.000 claims 2
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 claims 1
- NCQDNRMSPJIZKR-UHFFFAOYSA-N 4-[[1-(2,5-dioxopyrrolidin-1-yl)-2h-pyridin-2-yl]sulfanyl]pentanoic acid Chemical compound OC(=O)CCC(C)SC1C=CC=CN1N1C(=O)CCC1=O NCQDNRMSPJIZKR-UHFFFAOYSA-N 0.000 claims 1
- 102100022005 B-lymphocyte antigen CD20 Human genes 0.000 claims 1
- 201000009030 Carcinoma Diseases 0.000 claims 1
- 101000897405 Homo sapiens B-lymphocyte antigen CD20 Proteins 0.000 claims 1
- 102000008100 Human Serum Albumin Human genes 0.000 claims 1
- 108091006905 Human Serum Albumin Proteins 0.000 claims 1
- 102000038455 IGF Type 1 Receptor Human genes 0.000 claims 1
- 108010031794 IGF Type 1 Receptor Proteins 0.000 claims 1
- 102000003746 Insulin Receptor Human genes 0.000 claims 1
- 108010001127 Insulin Receptor Proteins 0.000 claims 1
- 102100031775 Leptin receptor Human genes 0.000 claims 1
- 102000007238 Transferrin Receptors Human genes 0.000 claims 1
- 108010033576 Transferrin Receptors Proteins 0.000 claims 1
- 102100032807 Tumor necrosis factor-inducible gene 6 protein Human genes 0.000 claims 1
- 101710169430 Tumor necrosis factor-inducible gene 6 protein Proteins 0.000 claims 1
- 238000010521 absorption reaction Methods 0.000 claims 1
- 150000001299 aldehydes Chemical class 0.000 claims 1
- 230000001588 bifunctional effect Effects 0.000 claims 1
- 210000003169 central nervous system Anatomy 0.000 claims 1
- 201000007455 central nervous system cancer Diseases 0.000 claims 1
- 238000001212 derivatisation Methods 0.000 claims 1
- 125000005442 diisocyanate group Chemical group 0.000 claims 1
- 150000002148 esters Chemical class 0.000 claims 1
- 230000029142 excretion Effects 0.000 claims 1
- 150000002222 fluorine compounds Chemical class 0.000 claims 1
- 229920002674 hyaluronan Polymers 0.000 claims 1
- 229960003160 hyaluronic acid Drugs 0.000 claims 1
- 150000002463 imidates Chemical class 0.000 claims 1
- 108010019813 leptin receptors Proteins 0.000 claims 1
- 230000014759 maintenance of location Effects 0.000 claims 1
- 230000004060 metabolic process Effects 0.000 claims 1
- 239000000126 substance Substances 0.000 claims 1
- CNHYKKNIIGEXAY-UHFFFAOYSA-N thiolan-2-imine Chemical compound N=C1CCCS1 CNHYKKNIIGEXAY-UHFFFAOYSA-N 0.000 claims 1
- 239000012581 transferrin Substances 0.000 claims 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/46—Hybrid immunoglobulins
- C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39541—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against normal tissues, cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2881—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD71
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2887—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD20
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/35—Valency
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/734—Complement-dependent cytotoxicity [CDC]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/31—Fusion polypeptide fusions, other than Fc, for prolonged plasma life, e.g. albumin
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
- C07K2319/735—Fusion polypeptide containing domain for protein-protein interaction containing a domain for self-assembly, e.g. a viral coat protein (includes phage display)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/90—Fusion polypeptide containing a motif for post-translational modification
- C07K2319/91—Fusion polypeptide containing a motif for post-translational modification containing a motif for glycosylation
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Engineering & Computer Science (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biomedical Technology (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Microbiology (AREA)
- Oncology (AREA)
- Neurology (AREA)
- Rheumatology (AREA)
- Neurosurgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Hematology (AREA)
- Hospice & Palliative Care (AREA)
- Ophthalmology & Optometry (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562235518P | 2015-09-30 | 2015-09-30 | |
| PCT/US2016/055041 WO2017059380A1 (en) | 2015-09-30 | 2016-09-30 | Binding molecules with modified j-chain |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| FI3355913T3 true FI3355913T3 (fi) | 2024-12-02 |
Family
ID=57153542
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| FIEP16784320.0T FI3355913T3 (fi) | 2015-09-30 | 2016-09-30 | Muokatun j-ketjun sisältäviä sitoutuvia molekyylejä |
Country Status (15)
| Country | Link |
|---|---|
| US (3) | US10618978B2 (enExample) |
| EP (2) | EP3355913B1 (enExample) |
| JP (2) | JP7065766B2 (enExample) |
| CN (1) | CN108463245A (enExample) |
| AU (2) | AU2016329197B2 (enExample) |
| CA (1) | CA2999284C (enExample) |
| DK (1) | DK3355913T3 (enExample) |
| ES (1) | ES2996834T3 (enExample) |
| FI (1) | FI3355913T3 (enExample) |
| HK (1) | HK1252791A1 (enExample) |
| HU (1) | HUE069387T2 (enExample) |
| PL (1) | PL3355913T3 (enExample) |
| PT (1) | PT3355913T (enExample) |
| SI (1) | SI3355913T1 (enExample) |
| WO (1) | WO2017059380A1 (enExample) |
Families Citing this family (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK3041862T3 (da) | 2013-09-05 | 2020-07-27 | Igm Biosciences Inc | Modificerede bispecifikke, penta- og hexavalente ig-m-antistoffer med konstant kæde |
| DK3105250T3 (da) | 2014-02-10 | 2020-09-28 | Igm Biosciences Inc | Multispecifikke iga-bindingsmolekyler |
| ES2717704T3 (es) | 2014-04-03 | 2019-06-24 | Igm Biosciences Inc | Cadena J modificada |
| PL3247728T3 (pl) | 2015-01-20 | 2020-11-16 | Igm Biosciences, Inc. | Cząsteczki wiążące receptor nadrodziny czynnika martwicy nowotworów (TNF) i ich stosowanie |
| SI3265575T1 (sl) * | 2015-03-04 | 2021-08-31 | Igm Biosciences, Inc. | Vezne molekule CD20 in njihove uporabe |
| EP3274051A4 (en) | 2015-03-25 | 2018-08-22 | IGM Biosciences A/S | Multi-valent hepatitis b virus antigen binding molecules and uses thereof |
| JP6811723B2 (ja) | 2015-04-17 | 2021-01-13 | アイジーエム バイオサイエンシズ インコーポレイテッド | 多価ヒト免疫不全ウイルス抗原結合分子およびその使用方法 |
| SI3355913T1 (sl) | 2015-09-30 | 2025-01-31 | Igm Biosciences, Inc. | Vezalne molekule z modificirano j-verigo |
| EP3356401B1 (en) | 2015-09-30 | 2020-06-24 | IGM Biosciences, Inc. | Binding molecules with modified j-chain |
| KR102343742B1 (ko) | 2016-05-09 | 2021-12-24 | 아이쥐엠 바이오사이언스 인코포레이티드 | 항-pd-l1 항체 |
| US11401337B2 (en) | 2017-04-07 | 2022-08-02 | Igm Biosciences, Inc. | Modified human IgM constant regions for modulation of complement-dependent cytolysis effector function |
| BR112020017296A2 (pt) * | 2018-03-01 | 2020-12-29 | Igm Biosciences, Inc. | Mutações de igm fc e de cadeia j que afetam a meia-vida sérica de igm |
| AU2020329301A1 (en) | 2019-08-15 | 2022-02-17 | Igm Biosciences, Inc. | Immunostimulatory multimeric binding molecules |
| WO2021034646A1 (en) * | 2019-08-17 | 2021-02-25 | Igm Biosciences, Inc. | Multimeric bispecific anti-cd123 binding molecules and uses thereof |
| US20220306760A1 (en) * | 2019-08-23 | 2022-09-29 | Igm Biosciences, Inc. | Igm glycovariants |
| WO2021141902A1 (en) * | 2020-01-06 | 2021-07-15 | Igm Biosciences, Inc. | Highly sialylated multimeric binding molecules |
| IL297029A (en) | 2020-04-22 | 2022-12-01 | Igm Biosciences Inc | Multimeric binding compounds as pd-1 agonists |
| US20240383998A1 (en) * | 2021-04-20 | 2024-11-21 | Korea University Research And Business Foundation | Asymmetric antibody with improved cytotoxicity against cancer cells |
| WO2022256740A1 (en) | 2021-06-04 | 2022-12-08 | Curia Ip Holdings, Llc | Polymeric fusion proteins and compositions for inducing an immune response against infection |
| JP2024528217A (ja) * | 2021-08-03 | 2024-07-26 | エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト | 二重特異性抗体および使用方法 |
Family Cites Families (157)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| GB8719963D0 (en) | 1987-08-24 | 1987-09-30 | Cattaneo A | Recombinant dna products |
| US5831034A (en) | 1987-11-13 | 1998-11-03 | Hermann Katinger | Human monoclonal anti-HIV-I-antibodies |
| US5175384A (en) | 1988-12-05 | 1992-12-29 | Genpharm International | Transgenic mice depleted in mature t-cells and methods for making transgenic mice |
| ATE314479T1 (de) | 1992-05-18 | 2006-01-15 | Genentech Inc | Aktivierung von rezeptoren fähig zur oligomerisierung durch verwendung von fusionierten rezeptor liganden |
| US6476198B1 (en) | 1993-07-13 | 2002-11-05 | The Scripps Research Institute | Multispecific and multivalent antigen-binding polypeptide molecules |
| UA40577C2 (uk) | 1993-08-02 | 2001-08-15 | Мерк Патент Гмбх | Біспецифічна молекула, що використовується для лізису пухлинних клітин, спосіб її одержання, моноклональне антитіло (варіанти), фармацевтичний препарат, фармацевтичний набір (варіанти), спосіб видалення пухлинних клітин |
| AU697387C (en) | 1994-09-16 | 2006-03-02 | Austin Research Institute Cancer and Anti-inflammatory Syndicate No 1 | Polypeptides with Fc binding ability |
| US5874540A (en) | 1994-10-05 | 1999-02-23 | Immunomedics, Inc. | CDR-grafted type III anti-CEA humanized mouse monoclonal antibodies |
| IL111196A0 (en) | 1994-10-07 | 1994-12-29 | Yeda Res & Dev | Peptides and pharmaceutical compositions comprising them |
| US6808709B1 (en) | 1994-12-30 | 2004-10-26 | The Regents Of The University Of California | Immunoglobulins containing protection proteins and their use |
| US6165463A (en) | 1997-10-16 | 2000-12-26 | Inhale Therapeutic Systems, Inc. | Dispersible antibody compositions and methods for their preparation and use |
| MX9708008A (es) | 1995-04-19 | 1998-03-31 | Polymun Scient Immunbio Forsch | Anticuerpos monoclonales contra vih-1 y vacunas hechas de los mismos. |
| US20050003431A1 (en) | 1996-08-16 | 2005-01-06 | Wucherpfennig Kai W. | Monovalent, multivalent, and multimeric MHC binding domain fusion proteins and conjugates, and uses therefor |
| US8212004B2 (en) | 1999-03-02 | 2012-07-03 | Human Genome Sciences, Inc. | Neutrokine-alpha fusion proteins |
| US6045774A (en) | 1997-01-10 | 2000-04-04 | Epicyte Pharmaceutical Inc. | J chain polypeptide targeting molecule linked to an imaging agent |
| US7311912B1 (en) | 1997-01-10 | 2007-12-25 | Plantbodies Corporation | Epithelial tissue targeting agent |
| US20040009166A1 (en) | 1997-04-30 | 2004-01-15 | Filpula David R. | Single chain antigen-binding polypeptides for polymer conjugation |
| AU3655899A (en) | 1998-04-20 | 1999-11-08 | Regents Of The University Of California, The | Modified immunoglobulin molecules and methods for use thereof |
| HK1041497B (en) | 1999-01-07 | 2004-06-18 | Zymogenetics, Inc. | Soluble receptor br43x2 and methods of using them for therapy |
| EP1169352A4 (en) | 1999-04-14 | 2005-05-04 | Smithkline Beecham Corp | ANTIBODY AGAINST THE ERYTHROPOIETIN RECEPTOR |
| JP4286483B2 (ja) | 1999-06-09 | 2009-07-01 | イムノメディクス， インコーポレイテッド | Ｂ細胞をターゲットとする抗体を使用する自己免疫疾患に対する免疫療法 |
| AU6781700A (en) | 1999-08-17 | 2001-03-13 | Health Research Institute | Genetic system and self-cleaving inteins derived therefrom, bioseparations and protein purification employing same, and methods for determining critical, generalizable amino acid residues for varying intein activity |
| CN1371416B (zh) | 1999-08-24 | 2012-10-10 | 梅达里克斯公司 | 人ctla-4抗体及其应用 |
| US20050287153A1 (en) | 2002-06-28 | 2005-12-29 | Genentech, Inc. | Serum albumin binding peptides for tumor targeting |
| HUP0300369A2 (hu) | 2000-04-11 | 2003-06-28 | Genentech, Inc. | Többértékű antitestek és alkalmazásuk |
| US20020168367A1 (en) | 2000-04-28 | 2002-11-14 | Planet Biotechnology Incorporated | Novel immunoadhesins for treating and preventing viral and bacterial diseases |
| EP1290027B1 (en) | 2000-04-28 | 2009-09-09 | Planet Biotechnology, Inc. | Immunoadhesin for the prevention of rhinovirus infection |
| EP2394659B1 (en) | 2000-05-10 | 2014-01-22 | Signe BioPharma Inc. | Compositions and methods for demonstrating secretory immune system regulation of steroid hormone responsive cancer cell growth |
| AU2001277531A1 (en) | 2000-07-10 | 2002-01-21 | Novartis Ag | Bifunctional molecules and vectors complexed therewith for targeted gene delivery |
| AU2004297218B2 (en) | 2000-09-07 | 2012-03-01 | Amgen, Inc. | Human anti-Pseudomonas-aeruginosa antibodies derived from transgenic Xenomouse |
| JP2004514423A (ja) | 2000-09-07 | 2004-05-20 | シュライバー， ジョン アール． | トランスジェニックｘｅｎｏｍｏｕｓｅ（登録商標）から獲得されるｐｅｕｄｏｍｏｎａｓａｅｒｕｇｉｎｏｓａｌｐｓに対するヒト抗体 |
| US7138496B2 (en) | 2002-02-08 | 2006-11-21 | Genetastix Corporation | Human monoclonal antibodies against human CXCR4 |
| US6596541B2 (en) | 2000-10-31 | 2003-07-22 | Regeneron Pharmaceuticals, Inc. | Methods of modifying eukaryotic cells |
| US7829084B2 (en) | 2001-01-17 | 2010-11-09 | Trubion Pharmaceuticals, Inc. | Binding constructs and methods for use thereof |
| US7754208B2 (en) | 2001-01-17 | 2010-07-13 | Trubion Pharmaceuticals, Inc. | Binding domain-immunoglobulin fusion proteins |
| KR20090010127A (ko) | 2001-03-07 | 2009-01-28 | 메르크 파텐트 게엠베하 | 하이브리드 이소타입 항체 부분구조를 포함하는 단백질을 위한 발현 기술 |
| US7402312B2 (en) * | 2001-04-13 | 2008-07-22 | Human Genome Sciences, Inc. | Antibodies to vascular endothelial growth factor 2 (VEGF-2) |
| US20050129616A1 (en) | 2001-05-25 | 2005-06-16 | Human Genome Sciences, Inc. | Antibodies that immunospecifically bind to TRAIL receptors |
| NZ513418A (en) | 2001-08-07 | 2004-04-30 | Univ Massey | Vaccine comprising proteins from mycobacterium paratuberculosis |
| AU2002356844C1 (en) | 2001-10-23 | 2010-03-04 | Amgen Fremont Inc. | PSMA antibodies and protein multimers |
| EP1519959B1 (en) | 2002-02-14 | 2014-04-02 | Immunomedics, Inc. | Anti-cd20 antibodies and fusion proteins thereof and methods of use |
| WO2003074566A2 (en) | 2002-03-01 | 2003-09-12 | Immunomedics, Inc. | Rs7 antibodies |
| ES2350477T5 (es) | 2002-03-01 | 2020-05-06 | Immunomedics Inc | Internalización de anticuerpos anti-CD74 y métodos de uso |
| IL164287A0 (en) | 2002-04-12 | 2005-12-18 | Medarex Inc | Methods of treatment using ctla-4 antibodies |
| WO2003106495A2 (en) | 2002-06-14 | 2003-12-24 | Immunomedics, Inc. | MONOCLONAL ANTIBODY hPAM4 |
| US7601351B1 (en) * | 2002-06-26 | 2009-10-13 | Human Genome Sciences, Inc. | Antibodies against protective antigen |
| JP4836451B2 (ja) | 2002-07-18 | 2011-12-14 | メルス ベー ヴェー | 抗体混合物の組換え生産 |
| CA2494310A1 (en) | 2002-08-01 | 2004-02-12 | Immunomedics, Inc. | Alpha-fetoprotein immu31 antibodies and fusion proteins and methods of use thereof |
| US20040156826A1 (en) | 2002-09-27 | 2004-08-12 | Fernando Dangond | Treatment of patients with multiple sclerosis based on gene expression changes in central nervous system tissues |
| US7541440B2 (en) | 2002-09-30 | 2009-06-02 | Immunomedics, Inc. | Chimeric, human and humanized anti-granulocyte antibodies and methods of use |
| US20050014932A1 (en) | 2003-05-15 | 2005-01-20 | Iogenetics, Llc | Targeted biocides |
| AR044388A1 (es) | 2003-05-20 | 2005-09-07 | Applied Molecular Evolution | Moleculas de union a cd20 |
| AU2004240782B2 (en) | 2003-05-23 | 2011-04-21 | Crucell Holland B.V. | Production of recombinant IGM in per.C6 cells |
| JP5452835B2 (ja) | 2003-07-15 | 2014-03-26 | 中外製薬株式会社 | 形質転換細胞によるＩｇＭの産生とその定量方法 |
| EP1648512A4 (en) | 2003-07-31 | 2009-01-21 | Immunomedics Inc | ANTI-CD19 ANTIBODIES |
| US8147832B2 (en) | 2003-08-14 | 2012-04-03 | Merck Patent Gmbh | CD20-binding polypeptide compositions and methods |
| EP1686137A4 (en) | 2003-10-09 | 2009-10-28 | Chugai Pharmaceutical Co Ltd | Method of stabilizing protein solutions |
| SI1673398T1 (sl) | 2003-10-16 | 2011-05-31 | Micromet Ag | Multispecifiäśne deimunizirajoäśe cd3 povezovalne molekule |
| FR2861255B1 (fr) | 2003-10-24 | 2006-02-17 | Centre Nat Rech Scient | Mammifere non-humain transgenique pour la region constante de la chaine lourde des immunoglobulines humaines de classe a et ses applications. |
| EP1697520A2 (en) | 2003-12-22 | 2006-09-06 | Xencor, Inc. | Fc polypeptides with novel fc ligand binding sites |
| JP5848861B2 (ja) | 2004-04-20 | 2016-01-27 | ジェンマブ エー／エスＧｅｎｍａｂ Ａ／Ｓ | Ｃｄ２０に対するヒトモノクローナル抗体 |
| BRPI0517057A (pt) | 2004-11-05 | 2008-09-30 | Palingen Inc | composição para induzir ferimento de membrana celular; composição para aumentar o ferimento da membrana celular em uma célula linfóide; composição para permeabilizar uma célula; composição para induzir ferimento da membrana celular em células b; composição para aumentar o ferimento da membrana celular induzido por um anticorpo de ferimento de membrana celular; método de tratamento de um mamìfero que sofre de uma condição distinta por uma hiperproliferação de células; método para matar uma célula cancerosa; método para induzir ferimento de membrana celular em uma célula linfóide em um paciente humano; método para induzir ferimento da membrana celular; método para permeabilizar uma célula; método de purgar a medula óssea de células b malignas de um paciente com esta necessidade; estojo para determinar o limite da dose para um agente polivalente que induz o ferimento da membrana celular em um mamìfero; estojo para determinar o limite da dose para um anticorpo de ferimento de membrana celular em um mamìfero; uso de um agente polivalente de ferimento de membrana celular; e uso de um anticorpo de ferimento de membrana celular |
| US7251164B2 (en) | 2004-11-10 | 2007-07-31 | Innovative Silicon S.A. | Circuitry for and method of improving statistical distribution of integrated circuits |
| EP1833848A2 (en) | 2004-12-09 | 2007-09-19 | Lajolla Institute for Allergy and Immunology | Novel tnf receptor regulatory domain |
| JP5214252B2 (ja) | 2005-03-03 | 2013-06-19 | イミューノメディクス、インコーポレイテッド | ヒト化ｌ２４３抗体 |
| US8349332B2 (en) | 2005-04-06 | 2013-01-08 | Ibc Pharmaceuticals, Inc. | Multiple signaling pathways induced by hexavalent, monospecific and bispecific antibodies for enhanced toxicity to B-cell lymphomas and other diseases |
| WO2006130458A2 (en) | 2005-06-02 | 2006-12-07 | Astrazeneca Ab | Antibodies directed to cd20 and uses thereof |
| US7612181B2 (en) | 2005-08-19 | 2009-11-03 | Abbott Laboratories | Dual variable domain immunoglobulin and uses thereof |
| AR056142A1 (es) | 2005-10-21 | 2007-09-19 | Amgen Inc | Metodos para generar el anticuerpo igg monovalente |
| CN101426521A (zh) | 2005-12-21 | 2009-05-06 | 医疗免疫有限责任公司 | EPHA2 BiTE分子及其应用 |
| WO2007134037A2 (en) | 2006-05-15 | 2007-11-22 | Immunomedics, Inc. | Methods and compositions for treatment of human immunodeficiency virus infection with conjugated antibodies or antibody fragments |
| US8268635B2 (en) | 2006-05-19 | 2012-09-18 | Antonio Ferrante | Methods of identifying agents that selectively activate p38 and/or NKkB signaling |
| EP3805269A1 (en) | 2006-06-12 | 2021-04-14 | Aptevo Research and Development LLC | Single-chain multivalent binding proteins with effector function |
| WO2008019147A2 (en) * | 2006-08-04 | 2008-02-14 | Amylin Pharmaceuticals, Inc. | Use of exendins, exendin agonists and glp-1 receptor agonists for altering the concentration of fibrinogen |
| HUE052220T2 (hu) | 2006-09-08 | 2021-04-28 | Abbvie Bahamas Ltd | Interleukin-13 kötõfehérjék |
| US9382327B2 (en) | 2006-10-10 | 2016-07-05 | Vaccinex, Inc. | Anti-CD20 antibodies and methods of use |
| CN101965363A (zh) | 2006-11-02 | 2011-02-02 | 丹尼尔·J·卡鹏 | 具有活动部分的杂合免疫球蛋白 |
| US20080145420A1 (en) * | 2006-12-13 | 2008-06-19 | Simon Michael R | HUMAN SECRETORY IgA FOR THE TREATMENT OF CLOSTRIDIUM DIFFICILE ASSOCIATED DISEASES |
| WO2008114011A2 (en) * | 2007-03-19 | 2008-09-25 | Medimmune Limited | Fc polypeptide variants obtained by ribosome display methodology |
| US20100298223A1 (en) | 2007-05-02 | 2010-11-25 | Dietmar Rudolf Fries | Fibrinogen for treatment of bleeding in trauma and platelet disorders |
| WO2009013620A2 (en) | 2007-06-11 | 2009-01-29 | Erasmus University Medical Center Rotterdam | Homologous recombination |
| AU2007358569B2 (en) | 2007-09-07 | 2014-09-04 | Ablynx N.V. | Binding molecules with multiple binding sites, compositions comprising the same and uses thereof |
| US8877688B2 (en) | 2007-09-14 | 2014-11-04 | Adimab, Llc | Rationally designed, synthetic antibody libraries and uses therefor |
| CA2706700A1 (en) | 2007-11-08 | 2009-05-14 | Cytimmune Sciences, Inc. | Compositions and methods for generating antibodies |
| EP2254592B1 (en) | 2008-02-28 | 2019-06-05 | Dako Denmark A/S | Mhc multimers in borrelia diagnostics and disease |
| ITTO20080313A1 (it) | 2008-04-22 | 2009-10-23 | Marco Colombatti | Anticorpo monoclonale isolato o suo frammento legante l'antigene specifico di membrana della prostata, suoi coniugati e suoi usi |
| US20100062950A1 (en) | 2008-07-11 | 2010-03-11 | Bhatt Ramesh R | Constructs and libraries comprising antibody surrogate kappa light chain sequences |
| WO2010037402A1 (en) | 2008-10-02 | 2010-04-08 | Dako Denmark A/S | Molecular vaccines for infectious disease |
| DK2356270T3 (da) | 2008-11-07 | 2016-12-12 | Fabrus Llc | Kombinatoriske antistofbiblioteker og anvendelser deraf |
| WO2010111414A1 (en) * | 2009-03-24 | 2010-09-30 | Bayer Healthcare Llc | Factor viii variants and methods of use |
| WO2011071957A1 (en) | 2009-12-07 | 2011-06-16 | Sea Lane Biotechnologies, Llc | Conjugates comprising an antibody surrogate scaffold with improved pharmacokinetic properties |
| JP5851419B2 (ja) | 2009-12-29 | 2016-02-03 | エマージェント プロダクト デベロップメント シアトル， エルエルシー | ヘテロダイマー結合タンパク質およびその使用 |
| EP2533810B1 (en) | 2010-02-10 | 2016-10-12 | ImmunoGen, Inc. | Cd20 antibodies and uses thereof |
| WO2011100538A1 (en) | 2010-02-11 | 2011-08-18 | Alexion Pharmaceuticals, Inc. | Therapeutic methods using an ti-cd200 antibodies |
| AU2011318567B2 (en) | 2010-10-19 | 2017-02-09 | Mayo Foundation For Medical Education And Research | Human antibodies and diagnostic and therapeutic uses thereof for the treatment of neurological disease |
| WO2012088290A2 (en) | 2010-12-22 | 2012-06-28 | Abbott Laboratories | Tri-variable domain binding proteins and uses thereof |
| PE20142245A1 (es) | 2011-10-24 | 2015-01-22 | Abbvie Inc | Inmunoligantes biespecificos dirigidos contra tnf e il-17 |
| GB201122047D0 (en) | 2011-12-21 | 2012-02-01 | Kymab Ltd | Transgenic animals |
| US9253965B2 (en) | 2012-03-28 | 2016-02-09 | Kymab Limited | Animal models and therapeutic molecules |
| WO2013087912A1 (en) | 2011-12-16 | 2013-06-20 | Synthon Biopharmaceuticals B.V. | Compounds and methods for treating inflammatory diseases |
| IN2014MN01781A (enExample) | 2012-02-08 | 2015-07-03 | Igm Biosciences Inc | |
| WO2013150138A1 (en) | 2012-04-05 | 2013-10-10 | Gottfried Himmler | Secretory immunoglobulin complex |
| EP3305323B1 (en) | 2012-04-17 | 2021-02-17 | Mayo Foundation for Medical Education and Research | Human antibodies and specific binding sequences thereof for use in stroke and ischemia or ischemic conditions |
| ES2671631T3 (es) | 2012-04-23 | 2018-06-07 | Nrl Pharma, Inc. | Proteína de fusión de lactoferrina y método para la preparación de la misma |
| WO2013188870A2 (en) | 2012-06-15 | 2013-12-19 | Beth Israel Deaconess Medical Center, Inc. | IgA CD4i ANTIBODIES AND METHODS OF TREATMENT USING SAME |
| JP2015524821A (ja) | 2012-08-02 | 2015-08-27 | ジェイエヌ バイオサイエンシーズ エルエルシー | システイン変異及びμ尾部を介して多量体化した抗体又は融合タンパク質 |
| JOP20200236A1 (ar) | 2012-09-21 | 2017-06-16 | Regeneron Pharma | الأجسام المضادة لمضاد cd3 وجزيئات ربط الأنتيجين ثنائية التحديد التي تربط cd3 وcd20 واستخداماتها |
| US10066238B2 (en) | 2013-02-11 | 2018-09-04 | University Of Louisville Research Foundation, Inc. | Methods for producing antibodies |
| US9487773B2 (en) | 2013-03-01 | 2016-11-08 | Technophage, Investigacao E Desenvolvimento Em Biotecnologia, Sa | Cell-based methods for coupling protein interactions and binding molecule selection |
| EP2968587A2 (en) * | 2013-03-13 | 2016-01-20 | Bristol-Myers Squibb Company | Fibronectin based scaffold domains linked to serum albumin or a moiety binding thereto |
| GB201311487D0 (en) | 2013-06-27 | 2013-08-14 | Alligator Bioscience Ab | Bispecific molecules |
| US20150038682A1 (en) | 2013-08-02 | 2015-02-05 | Jn Biosciences Llc | Antibodies or fusion proteins multimerized via homomultimerizing peptide |
| DK3041862T3 (da) | 2013-09-05 | 2020-07-27 | Igm Biosciences Inc | Modificerede bispecifikke, penta- og hexavalente ig-m-antistoffer med konstant kæde |
| WO2015037000A1 (en) | 2013-09-11 | 2015-03-19 | Compugen Ltd | Vstm5 polypeptides and uses thereof as a drug for treatment of cancer, infectious diseases and immune related diseases |
| WO2015103072A1 (en) | 2013-12-30 | 2015-07-09 | Epimab Biotherapeutics | Fabs-in-tandem immunoglobulin and uses thereof |
| EP3094644B1 (en) | 2014-01-16 | 2019-07-24 | Mondelli, Mario Umberto Franceso | Neutralizing human monoclonal antibodies against hepatitis b virus surface antigen |
| DK3105250T3 (da) | 2014-02-10 | 2020-09-28 | Igm Biosciences Inc | Multispecifikke iga-bindingsmolekyler |
| US20150259420A1 (en) | 2014-03-14 | 2015-09-17 | Novartis Ag | Antibody molecules to lag-3 and uses thereof |
| ES2717704T3 (es) | 2014-04-03 | 2019-06-24 | Igm Biosciences Inc | Cadena J modificada |
| PL3247728T3 (pl) | 2015-01-20 | 2020-11-16 | Igm Biosciences, Inc. | Cząsteczki wiążące receptor nadrodziny czynnika martwicy nowotworów (TNF) i ich stosowanie |
| SI3265575T1 (sl) | 2015-03-04 | 2021-08-31 | Igm Biosciences, Inc. | Vezne molekule CD20 in njihove uporabe |
| EP3274051A4 (en) | 2015-03-25 | 2018-08-22 | IGM Biosciences A/S | Multi-valent hepatitis b virus antigen binding molecules and uses thereof |
| JP6811723B2 (ja) | 2015-04-17 | 2021-01-13 | アイジーエム バイオサイエンシズ インコーポレイテッド | 多価ヒト免疫不全ウイルス抗原結合分子およびその使用方法 |
| AU2015242213A1 (en) | 2015-07-12 | 2018-03-08 | Hangzhou Dac Biotech Co., Ltd | Bridge linkers for conjugation of cell-binding molecules |
| EP3356401B1 (en) | 2015-09-30 | 2020-06-24 | IGM Biosciences, Inc. | Binding molecules with modified j-chain |
| SI3355913T1 (sl) | 2015-09-30 | 2025-01-31 | Igm Biosciences, Inc. | Vezalne molekule z modificirano j-verigo |
| KR102343742B1 (ko) | 2016-05-09 | 2021-12-24 | 아이쥐엠 바이오사이언스 인코포레이티드 | 항-pd-l1 항체 |
| WO2018017761A1 (en) | 2016-07-20 | 2018-01-25 | Igm Biosciences, Inc. | Multimeric cd137/4-1bb binding molecules and uses thereof |
| US20190330374A1 (en) | 2016-07-20 | 2019-10-31 | Igm Biosciences, Inc. | Multimeric ox40 binding molecules and uses thereof |
| WO2018017763A1 (en) | 2016-07-20 | 2018-01-25 | Igm Biosciences, Inc. | Multimeric cd40 binding molecules and uses thereof |
| CA3030659A1 (en) | 2016-07-20 | 2018-01-25 | Igm Biosciences, Inc. | Multimeric gitr binding molecules and uses thereof |
| US11401337B2 (en) | 2017-04-07 | 2022-08-02 | Igm Biosciences, Inc. | Modified human IgM constant regions for modulation of complement-dependent cytolysis effector function |
| CA3091140A1 (en) | 2018-02-26 | 2019-08-29 | Igm Biosciences, Inc. | Use of a multimeric anti-dr5 binding molecule in combination with a chemotherapeutic agent for treating cancer |
| BR112020017296A2 (pt) | 2018-03-01 | 2020-12-29 | Igm Biosciences, Inc. | Mutações de igm fc e de cadeia j que afetam a meia-vida sérica de igm |
| KR20210083260A (ko) | 2018-10-23 | 2021-07-06 | 아이쥐엠 바이오사이언스 인코포레이티드 | 다가 IgM- 및 IgA-Fc 기반 결합 분자 |
| WO2020163646A1 (en) | 2019-02-08 | 2020-08-13 | Igm Biosciences, Inc. | Anti-gitr antigen-binding domains and uses thereof |
| AU2020329301A1 (en) | 2019-08-15 | 2022-02-17 | Igm Biosciences, Inc. | Immunostimulatory multimeric binding molecules |
| WO2021034646A1 (en) | 2019-08-17 | 2021-02-25 | Igm Biosciences, Inc. | Multimeric bispecific anti-cd123 binding molecules and uses thereof |
| US20220306760A1 (en) | 2019-08-23 | 2022-09-29 | Igm Biosciences, Inc. | Igm glycovariants |
| WO2021055765A2 (en) | 2019-09-19 | 2021-03-25 | Igm Biosciences, Inc. | Multimeric antibodies with enhanced selectivity for cells with high target density |
| WO2021141902A1 (en) | 2020-01-06 | 2021-07-15 | Igm Biosciences, Inc. | Highly sialylated multimeric binding molecules |
| IL297029A (en) | 2020-04-22 | 2022-12-01 | Igm Biosciences Inc | Multimeric binding compounds as pd-1 agonists |
| KR20230010221A (ko) | 2020-05-12 | 2023-01-18 | 아이쥐엠 바이오사이언스 인코포레이티드 | 암 치료를 위한 암 요법과 병용된 다량체 항-dr5 결합 분자의 용도 |
| EP4188951A4 (en) | 2020-07-27 | 2024-08-28 | IGM Biosciences, Inc. | Multimeric coronavirus binding molecules and uses thereof |
| WO2022109023A1 (en) | 2020-11-17 | 2022-05-27 | Igm Biosciences, Inc. | Uses of effector cell engaging molecules with moieties of differing potencies |
| AU2022221633A1 (en) | 2021-02-17 | 2023-08-10 | Igm Biosciences, Inc. | Anti-cd123 binding molecules and uses thereof |
| US20220267415A1 (en) | 2021-02-17 | 2022-08-25 | The Board Of Regents Of The University Of Texas System | Multimeric sars-cov-2 binding molecules and uses thereof |
| WO2023064766A1 (en) | 2021-10-11 | 2023-04-20 | Igm Biosciences, Inc. | Lateral flow device and uses thereof |
| WO2023064900A1 (en) | 2021-10-15 | 2023-04-20 | Igm Biosciences, Inc. | Methods of use of multimeric anti-pd-l1 binding molecules |
| IL313350A (en) | 2022-02-03 | 2024-08-01 | Igm Biosciences Inc | CD38 binding compounds and uses thereof |
| WO2023178253A2 (en) | 2022-03-18 | 2023-09-21 | Igm Biosciences, Inc. | Use of a multimeric anti-pd-l1 binding molecule in combination with a monoclonal antibody therapy |
| WO2024073700A2 (en) | 2022-09-30 | 2024-04-04 | Igm Biosciences, Inc. | Methods of treating autoimmune disorders using multimeric anti-cd20/anti-cd3 antibodies |
| WO2024138072A1 (en) | 2022-12-22 | 2024-06-27 | Igm Biosciences, Inc. | Methods of treating autoimmune disorders using multimeric anti-cd38/anti-cd3 antibodies |
| WO2024148336A1 (en) | 2023-01-06 | 2024-07-11 | Igm Biosciences, Inc. | T cell costimulatory multimeric binding molecules and uses thereof |
| WO2024148339A1 (en) | 2023-01-06 | 2024-07-11 | Igm Biosciences, Inc. | Use of a multimeric anti-dr5 antibody for treating cancer |
| WO2024229151A2 (en) | 2023-05-02 | 2024-11-07 | Igm Biosciences, Inc. | Multimeric coronavirus binding molecules and uses thereof |
-
2016
- 2016-09-30 SI SI201631864T patent/SI3355913T1/sl unknown
- 2016-09-30 HK HK18111023.8A patent/HK1252791A1/zh unknown
- 2016-09-30 ES ES16784320T patent/ES2996834T3/es active Active
- 2016-09-30 US US15/764,859 patent/US10618978B2/en active Active
- 2016-09-30 DK DK16784320.0T patent/DK3355913T3/da active
- 2016-09-30 JP JP2018516668A patent/JP7065766B2/ja active Active
- 2016-09-30 EP EP16784320.0A patent/EP3355913B1/en active Active
- 2016-09-30 AU AU2016329197A patent/AU2016329197B2/en active Active
- 2016-09-30 CA CA2999284A patent/CA2999284C/en active Active
- 2016-09-30 HU HUE16784320A patent/HUE069387T2/hu unknown
- 2016-09-30 CN CN201680069842.XA patent/CN108463245A/zh active Pending
- 2016-09-30 PL PL16784320.0T patent/PL3355913T3/pl unknown
- 2016-09-30 FI FIEP16784320.0T patent/FI3355913T3/fi active
- 2016-09-30 EP EP20204954.0A patent/EP3824903A1/en not_active Withdrawn
- 2016-09-30 PT PT167843200T patent/PT3355913T/pt unknown
- 2016-09-30 WO PCT/US2016/055041 patent/WO2017059380A1/en not_active Ceased
-
2020
- 2020-01-16 US US16/745,059 patent/US11542342B2/en active Active
-
2021
- 2021-01-20 AU AU2021200348A patent/AU2021200348B2/en active Active
-
2022
- 2022-04-26 JP JP2022072055A patent/JP7314356B2/ja active Active
- 2022-11-11 US US18/054,776 patent/US12486336B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| PL3355913T3 (pl) | 2025-02-17 |
| US20180265596A1 (en) | 2018-09-20 |
| PT3355913T (pt) | 2024-12-18 |
| SI3355913T1 (sl) | 2025-01-31 |
| JP2018535932A (ja) | 2018-12-06 |
| WO2017059380A1 (en) | 2017-04-06 |
| US20200255546A1 (en) | 2020-08-13 |
| EP3355913B1 (en) | 2024-10-30 |
| CA2999284C (en) | 2023-06-13 |
| JP7314356B2 (ja) | 2023-07-25 |
| AU2021200348B2 (en) | 2024-07-11 |
| HK1252791A1 (zh) | 2019-06-06 |
| US10618978B2 (en) | 2020-04-14 |
| US12486336B2 (en) | 2025-12-02 |
| AU2021200348A1 (en) | 2021-03-18 |
| US20230203201A1 (en) | 2023-06-29 |
| HUE069387T2 (hu) | 2025-03-28 |
| EP3824903A1 (en) | 2021-05-26 |
| AU2016329197B2 (en) | 2021-01-21 |
| ES2996834T3 (en) | 2025-02-13 |
| CN108463245A (zh) | 2018-08-28 |
| CA2999284A1 (en) | 2017-04-06 |
| AU2016329197A1 (en) | 2018-04-12 |
| US11542342B2 (en) | 2023-01-03 |
| DK3355913T3 (da) | 2024-12-02 |
| EP3355913A1 (en) | 2018-08-08 |
| JP7065766B2 (ja) | 2022-05-12 |
| JP2022105085A (ja) | 2022-07-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| FI3355913T3 (fi) | Muokatun j-ketjun sisältäviä sitoutuvia molekyylejä | |
| US11986535B2 (en) | Method of producing an immunoligand/payload conjugate | |
| JP2018535932A5 (enExample) | ||
| Wagner et al. | Bispecific antibody generated with sortase and click chemistry has broad antiinfluenza virus activity | |
| AU2021201710B9 (en) | Binding protein drug conjugates comprising anthracycline derivatives | |
| Monnier et al. | In vivo applications of single chain Fv (variable domain)(scFv) fragments | |
| Forte et al. | Tuning the hydrolytic stability of next generation maleimide cross-linkers enables access to albumin-antibody fragment conjugates and tri-scFvs | |
| EP2994164B1 (en) | Bispecific her2 and her3 antigen binding constructs | |
| US8728479B2 (en) | Antigen-binding proteins comprising recombinant protein scaffolds | |
| Kornberger et al. | Sortase-catalyzed in vitro functionalization of a HER2-specific recombinant Fab for tumor targeting of the plant cytotoxin gelonin | |
| Mertens | Tribodies: fab–scfv fusion proteins as a platform to create multifunctional pharmaceuticals | |
| Woitok et al. | The efficient elimination of solid tumor cells by EGFR-specific and HER2-specific scFv-SNAP fusion proteins conjugated to benzylguanine-modified auristatin F | |
| JP2019013232A (ja) | 志賀毒素ａサブユニットエフェクター領域を含む多価ｃｄ２０結合分子及びそれらの強化組成物 | |
| RU2020103344A (ru) | Конъюгаты антител с лекарственными средствами, характеризующиеся высокой in vivo переносимостью | |
| SI2802606T1 (en) | Improves the transfer of healing molecules through the hematoencephalic barrier | |
| BRPI0214137B8 (pt) | anticorpo monoclonal humano ou porção de ligação a antígeno do mesmo que se liga especificamente ao cd40 humano e o ativa, linhagem celular de hibridoma isolado, composição farmacêutica compreendendo os mesmos, uso dos mesmos na fabricação de um medicamento e método de fabricação dos referidos anticorpos ou porção de ligação a antígeno do mesmo | |
| JP2014502607A (ja) | 抗ｄｉｇ抗体およびペプチドと結合体化しているジゴキシゲニンの複合体の薬学的組成物 | |
| WO2017060322A3 (en) | Ptefb-inhibitor-adc | |
| Humphreys et al. | Alternative antibody Fab′ fragment PEGylation strategies: combination of strong reducing agents, disruption of the interchain disulphide bond and disulphide engineering | |
| JP2022509372A (ja) | 血液脳関門輸送の促進のためのヒト化され安定化されたｆｃ５バリアント | |
| Fuchs et al. | A cleavable molecular adapter reduces side effects and concomitantly enhances efficacy in tumor treatment by targeted toxins in mice | |
| Forouharmehr et al. | Production and introduction of a novel immunotoxin based on engineered RNase A for inducing death to Her1‐positive cell lines | |
| Watanabe et al. | Scale-up synthesis of site-specific antibody–drug conjugates using AJICAP second-generation technology | |
| Panjideh et al. | Improved therapy of B-cell non-hodgkin lymphoma by obinutuzumab-dianthin conjugates in combination with the endosomal escape enhancer SO1861 | |
| Lee et al. | Enhancing the cytotoxicity of immunotoxins by facilitating their dissociation from target receptors under the reducing conditions of the endocytic pathway |